View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBionomics 배당 및 자사주 매입배당 기준 점검 0/6Bionomics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-108.6%자사주 매입 수익률총 주주 수익률-108.6%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (80% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.72m market cap, or US$9.42m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$3.9m).공시 • Aug 24Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress DisorderBionomics Limited announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD. The Phase 2b ATTUNE study (NCT04951076) is a double-blind, placebo-controlled, randomized study of twice daily BNC210 as monotherapy treatment for PTSD. The primary endpoint is change in a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scores from baseline to week 12 compared to placebo. Secondary endpoints include change from baseline to week 12 compared to placebo on the PTSD-checklist (PCL-5), anxiety (Hamilton Anxiety Rating Scale, HAM-A), depression (Montgomery-Asberg Depression Rating Scale, MADRS), Clinician Global Impression (CGI), Patient Global Impression (PGI), sleep (Insomnia Severity Index, ISI) and disability (Sheehan Disability Scale, SDS) scales. Approximately 200 participants have been enrolled at 27 sites in the United States and 7 sites in the United Kingdom, and topline results are anticipated by the end of September 2023. The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023. At this meeting, Bionomics will discuss with the FDA its plans for a Phase 3 program that would support the submission of a new drug application for BNC210 for the treatment of SAD. The Company believes that the results from Phase 2 PREVAIL study support the progression of BNC210 into Phase 3 and plans to provide an update by the end of 2023 following the receipt of formal meeting minutes from the FDA.New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.85m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (72% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.85m market cap, or US$9.71m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$4.0m).공시 • Jul 04+ 1 more updateBionomics Limited Appoints Tim Cunningham as Chief Financial OfficerBionomics Limited announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive member of the Board since 1 September 2016 and Chair of the Audit & Risk Committee, has been appointed Non-Executive Chair of the Board, effective from 1 July 2023. Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director. Tim Cunningham of Danforth Associates has been appointed Chief Financial Officer effective 1 July 2023. This appointment is in continuation to the ongoing expansion of the leadership team that began in 2023 with the appointment of Julie Kerner, Ph.D., as Senior Vice President of Business Operations, and Atul R. Mahableshwarkar, MD, as the Acting Chief Medical Officer. The Company has also engaged Francisco Bejar as a strategic advisor to head the business development efforts in the U.S. and abroad, whilst Connor Bernstein, Vice President, Strategy and Development, steps down from his role with effect from 30 June 2023. Mr. Fisheris an experienced corporate advisor and public company director, with a proven track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is currently a Non-Executive Director and Chair of Centrepoint Alliance Limited and Non-Executive Director and Chair of the Audit and Risk Committee of Thorney Technologies Limited Mr. Cunningham has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company’s growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida. Dr. Kerner brings over 15 years of experience where under her leadership companies created portfolio and platform strategies, built new therapeutic areas, filed over 10 IND/CTAs, conducted proof of concept and Phase 3 trials, and launched multiple therapeutics. Dr Kerner has worked at Biogen, AVROBIO, Wave Life Sciences and most recently Fulcrum Therapeutics and Aliada Therapeutics, where she was responsible for driving pipeline strategy and program leadership. Dr. Kerner is a board member of Newton Wellesley Hospital, National Braille Press, and the U.S. Neuroacanthocytosis advocacy Inc. Dr. Mahableshwarkar is a board-certified psychiatrist with over 20 years of strategic, developmental, and regulatory experience in large global and small startup companies who have submitted INDs and NDAs leading to drug approvals. He has had leadership roles as Chief Medical Officer and Senior Vice President/Vice President for Clinical Development in Emalex Biosciences and BlackThorn Therapeutics, where he provided strategy and oversight of the clinical program from proof of concept to drug approval. The company has also engaged Mr. Francisco Bejar as a Strategic Business Development Advisor to lead the Company’s partnering efforts for BNC210, the company’s preclinical assets (KV3 and Nav1.7/1.8 programs) and our legacy oncology portfolio both in the U.S. and ex-U.S.Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share. Net loss: AU$16.2m (loss widened 24% from 1H 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.Board Change • Feb 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO, President & Director Spyros Papapetropoulos was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 18High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 26Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)Full year 2022 results: AU$0.016 loss per share (down from AU$0.011 loss in FY 2021). Net loss: AU$21.8m (loss widened 150% from FY 2021). Over the next year, revenue is forecast to grow 44%, compared to a 10% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 07High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Dec 31High number of new directorsMember of Clinical Advisory Board Srini Rao was the last director to join the board, commencing their role in 2021.Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)Full year 2021 results: Net loss: AU$8.70m (loss widened 50% from FY 2020). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Executive Departure • Mar 25Legal Counsel & Company Secretary has left the companyOn the 23rd of March, Jack Moschakis' tenure as Legal Counsel & Company Secretary ended after 5.9 years in the role. As of December 2020, Jack personally held only 35.52k shares (€2.7k worth at the time). A total of 2 executives have left over the last 12 months.Analyst Estimate Surprise Post Earnings • Mar 04Revenue beats expectationsRevenue exceeded analyst estimates by 43%.Is New 90 Day High Low • Feb 19New 90-day high: €0.27The company is up 309% from its price of €0.066 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 B1N 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: B1N 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Bionomics 배당 수익률 vs 시장B1N의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (B1N)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.2%분석가 예측 (B1N) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 B1N 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 B1N 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 B1N 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: B1N 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/09/01 06:46종가2023/08/24 00:00수익2022/12/31연간 수익2022/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Neuphoria Therapeutics Inc.는 5명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tanushree JainBell PotterEsther Lannie HongBerenbergKatherine GenisEdison Investment Research2명의 분석가 더 보기
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (80% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.72m market cap, or US$9.42m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$3.9m).
공시 • Aug 24Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress DisorderBionomics Limited announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD. The Phase 2b ATTUNE study (NCT04951076) is a double-blind, placebo-controlled, randomized study of twice daily BNC210 as monotherapy treatment for PTSD. The primary endpoint is change in a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scores from baseline to week 12 compared to placebo. Secondary endpoints include change from baseline to week 12 compared to placebo on the PTSD-checklist (PCL-5), anxiety (Hamilton Anxiety Rating Scale, HAM-A), depression (Montgomery-Asberg Depression Rating Scale, MADRS), Clinician Global Impression (CGI), Patient Global Impression (PGI), sleep (Insomnia Severity Index, ISI) and disability (Sheehan Disability Scale, SDS) scales. Approximately 200 participants have been enrolled at 27 sites in the United States and 7 sites in the United Kingdom, and topline results are anticipated by the end of September 2023. The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023. At this meeting, Bionomics will discuss with the FDA its plans for a Phase 3 program that would support the submission of a new drug application for BNC210 for the treatment of SAD. The Company believes that the results from Phase 2 PREVAIL study support the progression of BNC210 into Phase 3 and plans to provide an update by the end of 2023 following the receipt of formal meeting minutes from the FDA.
New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.85m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (72% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.85m market cap, or US$9.71m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$4.0m).
공시 • Jul 04+ 1 more updateBionomics Limited Appoints Tim Cunningham as Chief Financial OfficerBionomics Limited announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive member of the Board since 1 September 2016 and Chair of the Audit & Risk Committee, has been appointed Non-Executive Chair of the Board, effective from 1 July 2023. Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director. Tim Cunningham of Danforth Associates has been appointed Chief Financial Officer effective 1 July 2023. This appointment is in continuation to the ongoing expansion of the leadership team that began in 2023 with the appointment of Julie Kerner, Ph.D., as Senior Vice President of Business Operations, and Atul R. Mahableshwarkar, MD, as the Acting Chief Medical Officer. The Company has also engaged Francisco Bejar as a strategic advisor to head the business development efforts in the U.S. and abroad, whilst Connor Bernstein, Vice President, Strategy and Development, steps down from his role with effect from 30 June 2023. Mr. Fisheris an experienced corporate advisor and public company director, with a proven track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is currently a Non-Executive Director and Chair of Centrepoint Alliance Limited and Non-Executive Director and Chair of the Audit and Risk Committee of Thorney Technologies Limited Mr. Cunningham has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company’s growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida. Dr. Kerner brings over 15 years of experience where under her leadership companies created portfolio and platform strategies, built new therapeutic areas, filed over 10 IND/CTAs, conducted proof of concept and Phase 3 trials, and launched multiple therapeutics. Dr Kerner has worked at Biogen, AVROBIO, Wave Life Sciences and most recently Fulcrum Therapeutics and Aliada Therapeutics, where she was responsible for driving pipeline strategy and program leadership. Dr. Kerner is a board member of Newton Wellesley Hospital, National Braille Press, and the U.S. Neuroacanthocytosis advocacy Inc. Dr. Mahableshwarkar is a board-certified psychiatrist with over 20 years of strategic, developmental, and regulatory experience in large global and small startup companies who have submitted INDs and NDAs leading to drug approvals. He has had leadership roles as Chief Medical Officer and Senior Vice President/Vice President for Clinical Development in Emalex Biosciences and BlackThorn Therapeutics, where he provided strategy and oversight of the clinical program from proof of concept to drug approval. The company has also engaged Mr. Francisco Bejar as a Strategic Business Development Advisor to lead the Company’s partnering efforts for BNC210, the company’s preclinical assets (KV3 and Nav1.7/1.8 programs) and our legacy oncology portfolio both in the U.S. and ex-U.S.
Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share. Net loss: AU$16.2m (loss widened 24% from 1H 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
Board Change • Feb 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO, President & Director Spyros Papapetropoulos was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 18High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 26Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)Full year 2022 results: AU$0.016 loss per share (down from AU$0.011 loss in FY 2021). Net loss: AU$21.8m (loss widened 150% from FY 2021). Over the next year, revenue is forecast to grow 44%, compared to a 10% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 07High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Dec 31High number of new directorsMember of Clinical Advisory Board Srini Rao was the last director to join the board, commencing their role in 2021.
Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)Full year 2021 results: Net loss: AU$8.70m (loss widened 50% from FY 2020). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Executive Departure • Mar 25Legal Counsel & Company Secretary has left the companyOn the 23rd of March, Jack Moschakis' tenure as Legal Counsel & Company Secretary ended after 5.9 years in the role. As of December 2020, Jack personally held only 35.52k shares (€2.7k worth at the time). A total of 2 executives have left over the last 12 months.
Analyst Estimate Surprise Post Earnings • Mar 04Revenue beats expectationsRevenue exceeded analyst estimates by 43%.
Is New 90 Day High Low • Feb 19New 90-day high: €0.27The company is up 309% from its price of €0.066 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.